News
The tennis star has sparked an online debate about whether or not using GLP-1s for weight loss is taking the easy way out.
About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...
Green Matters on MSN6d
Ozempic Sparks Both Weight Loss Success Stories and Major Lawsuits in 2025
The weight loss injectable Ozempic has faced several lawsuits in 2025 from people who had a negative experience with the ...
(Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback